Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary.

GlobeNewsWire • Feb 17, 2026

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting, held on Jan 24, 2026 in Orlando, Florida.

GlobeNewsWire • Jan 30, 2026

Nutriband CEO Publishes Letter to Shareholders

ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026.

GlobeNewsWire • Dec 31, 2025

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition The expected closing date for the transaction is Dec 31, 2025. ORLANDO, Fla.

GlobeNewsWire • Dec 29, 2025

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. Illicit fentanyl and its core precursor chemicals have been designated as weapons of mass destruction to enable the US government to combat the manufacture and distribution by cartels and foreign networks that have flooded the US with illegal fentanyl.

GlobeNewsWire • Dec 18, 2025

Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference

Orlando, Florida--(Newsfile Corp. - November 24, 2025) - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman and Co-Founder, Serguei Melnik will present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.- on Wednesday, December 3rd at 9.30 AM Eastern Standard Time.

Newsfile Corp • Nov 24, 2025

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.

GlobeNewsWire • Oct 28, 2025

REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.

GlobeNewsWire • Oct 28, 2025

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system. Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.

GlobeNewsWire • Oct 10, 2025

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing  opioids and stimulants with a potential for abuse. Nutriband's AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.

GlobeNewsWire • Oct 8, 2025